Management of Type 1 Diabetes and Hypertension in Pregnancy

Immediate Diabetes Management

The American Diabetes Association recommends using insulin exclusively for glycemic control in pregnant women with type 1 diabetes, as insulin does not cross the placenta and provides the safest option for both mother and fetus 1, 2, 3
Either multiple daily injections with basal-bolus regimen or continuous subcutaneous insulin infusion (pump) are acceptable for glycemic control in pregnant women with type 1 diabetes, with no proven superiority of one method over the other 1, 2, 4
At 9 months gestation, insulin requirements should have plateaued or may even be decreasing, with a rapid drop in insulin needs indicating potential placental insufficiency and requiring immediate evaluation 5
Expect insulin requirements to drop dramatically immediately after delivery, requiring reduction to 50% of end-pregnancy doses to prevent severe hypoglycemia 3

The American College of Obstetricians and Gynecologists recommends fasting glucose targets of <95 mg/dL and 1-hour postprandial targets of <140 mg/dL for pregnant women with type 1 diabetes 6
The American Diabetes Association recommends an A1C target of <6% if achievable without significant hypoglycemia, otherwise <7% for pregnant women with type 1 diabetes 6, 3

The American College of Cardiology recommends immediately discontinuing ACE inhibitors and ARBs in pregnant women with hypertension and type 1 diabetes, due to fetal renal anomalies, oligohydramnios, and fetal death, and switching to pregnancy-safe antihypertensives such as methyldopa, labetalol, or long-acting nifedipine 7
Target blood pressure should be 110-135/85 mmHg to reduce accelerated maternal hypertension while minimizing impaired fetal growth 7

The American Heart Association recommends low-dose aspirin 100-150 mg daily for pregnant women with type 1 diabetes and hypertension to reduce preeclampsia risk, which should be started at 12-16 weeks gestation 1, 2, 3, 7

The American College of Obstetricians and Gynecologists recommends monitoring closely for signs of preeclampsia, such as severe headache, visual changes, right upper quadrant pain, sudden weight gain, and proteinuria, as diabetes substantially increases preeclampsia risk 8, 4, 3
The American Academy of Ophthalmology recommends ensuring retinopathy screening has been completed, as rapid glucose normalization can worsen existing retinopathy, and close ophthalmologic monitoring should have occurred throughout pregnancy if retinopathy was present 3, 6

The American College of Obstetricians and Gynecologists recommends coordinating with maternal-fetal medicine and neonatology teams for delivery planning, preparing for immediate postpartum insulin dose reduction to prevent severe hypoglycemia, and anticipating potential neonatal complications including hypoglycemia, respiratory distress, and macrosomia 1, 2, 3, 6
The Endocrine Society recommends reducing insulin immediately after delivery to 50% of end-pregnancy doses or 80% of pre-pregnancy doses, and monitoring glucose closely, especially if breastfeeding, as this further increases hypoglycemia risk 3

The American Diabetes Association recommends ensuring coordination between endocrinology, maternal-fetal medicine, obstetrics, and neonatology for managing type 1 diabetes with hypertension in late pregnancy, as this requires specialized team-based care 1, 2, 4, 3

In pregnant individuals with pre‑existing diabetes, pooled data show that approximately 15 % develop new retinopathy and 6.3 % progress from non‑proliferative to proliferative disease per 100 pregnancies. [9] [10] 11
Initiating intensive glycemic control rapidly may paradoxically worsen existing retinopathy in this population. [9] [12] 11

Dilated ophthalmic examination each trimester is advised for pregnant patients with pre‑existing diabetes; the exam should specifically evaluate for macular edema, neovascularization, and vitreous hemorrhage. [13] [14]
Immediate referral to an ophthalmologist is recommended when any level of diabetic macular edema, moderate‑or‑worse non‑proliferative diabetic retinopathy, or any proliferative diabetic retinopathy is identified. [10] [11]
Gestational diabetes alone does not require routine eye examinations during pregnancy, and these patients are not at increased risk for diabetic retinopathy. [13] [14] [9] [10] 11

Laser photocoagulation is effective in reducing vision loss for high‑risk proliferative diabetic retinopathy or center‑involved diabetic macular edema when performed during pregnancy. [9] [11]
Anti‑VEGF agents should be avoided in pregnant patients because of theoretical fetal vascular toxicity. [9] [11]